MicroRNAs as non-invasive screening biomarkers of colorectal cancer

Saplacan, Roberta Maria Manzat; Mircea, Petru Adrian; Bălăcescu, Loredana; Bălăcescu, Ovidiu

doi:10.15386/cjmed-568

Cited by 8 publications

(6 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Profiling of miRNAs can give insight as biomarkers for diagnostic or prognostic applications. For example, panels of miRNAs can be used to classify different cancer phenotypes, predict recurrence or response to therapies [ 1 , 12 , 29 – 31 ]. However, for discovery and clinical application of miRNA-based biomarkers there needs to be optimised and standardised practices for how the RNA is extracted to prevent conflicting results.…”

Section: Discussionmentioning

confidence: 99%

Total RNA extraction from tissues for microRNA and target gene expression analysis: not all kits are created equal

et al. 2018

View full text Add to dashboard Cite

BackgroundmicroRNAs (miRNAs) are short non-coding RNAs that fine-tune gene expression. The aberrant expression of miRNAs is associated with many diseases and they have both therapeutic and biomarker potential. However, our understanding of their usefulness is dependent on the tools we have to study them. Previous studies have identified the need to optimise and standardise RNA extraction methods in order to avoid biased results. Herein, we extracted RNA from murine lung, liver and brain tissues using five commercially available total RNA extraction methods. These included either: phenol: chloroform extraction followed by alcohol precipitation (TRIzol), phenol:chloroform followed by solid-phase extraction (column-based; miRVana and miRNeasy) and solid-phase separation with/without affinity resin (Norgen total and Isolate II). We then evaluated each extraction method for the quality and quantity of RNA recovered, and the expression of miRNAs and target genes.ResultsWe identified differences between each of the RNA extraction methods in the quantity and quality of RNA samples, and in the analysis of miRNA and target gene expression. For the purposes of consistency in quantity, quality and high recovery of miRNAs from tissues, we identified that Phenol:chloroform phase separation combined with silica column-based solid extraction method was preferable (miRVana microRNA isolation). We also identified a method that is not appropriate for miRNA analysis from tissue samples (Bioline Isolate II). For target gene expression any of the kits could be used to analyse mRNA, but if interested in analysing mRNA and miRNA from the same RNA samples some methods should be avoided.ConclusionsDifferent methods used to isolate miRNAs will yield different results and therefore a robust RNA isolation method is required for reproducibility. Researchers should optimise these methods for their specific application and keep in mind that “total RNA” extraction methods do not isolate all types of RNA equally.Electronic supplementary materialThe online version of this article (10.1186/s12896-018-0421-6) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 99%

Total RNA extraction from tissues for microRNA and target gene expression analysis: not all kits are created equal

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Furthermore, expression profiles of miRNAs in the plasma and/or serum of cancer patients may reflect the change in miRNA expression in tumor cells ( 42 ). Circulating miRNAs may be a novel class of non-invasive biomarkers for cancer diagnostic and prognostic information ( 43 , 44 ). The differential expression of miR-10a/b in different AML subtypes should be validated in more clinical samples to develop a novel method for subtyping AML according to miRNA expression.…”

Section: Discussionmentioning

confidence: 99%

MicroRNA-10a/b are regulators of myeloid differentiation and acute myeloid leukemia

Sun

Jin

et al. 2018

Oncol Lett

View full text Add to dashboard Cite

MicroRNAs (miRs) have been demonstrated to perform important roles in normal hematopoiesis and leukemogenesis. Accumulating evidence suggests that miR-10a and miR-10b may behave as novel oncogenes or tumor suppressors in human cancer. The present study reported the function of the miR-10 family in myeloid differentiation and acute myeloid leukemia (AML). The levels of miR-10a/b expression were increased in AML cases compared with normal controls, particularly in M1, M2 and M3 subtypes. The levels of miR-10a/b expression were also upregulated in patients with nucleophosmin-mutated AML and AML patients with t(8;21) and t(9;11), compared with the normal control. In addition, the role of miR-10a/b in regulating myeloid differentiation and leukemogenesis was investigated. The results indicated that miR-10a/b expression was able to promote the proliferation of human promyelocytic leukemia cells, while suppressing the granulocytic and monocytic differentiation of the leukemia cells. These findings suggested that abnormal high expression of miR-10a/b may result in unlimited proliferation of immature blood progenitors and repression of mature blood cell differentiation and maturation, thus leading to the occurrence of AML. miR-10a/b may be developed as novel therapeutic targets for the treatment of AML.

show abstract

“…Within the last decade a number of researchers have demonstrated that long non-coding RNAs (lncRNAs) are stable in blood and have diagnostic potential [ 148 , 149 , 150 , 151 ]. Based on length, ncRNAs are divided into two classes: small non-coding RNAs, whose length is a maximum of 200 nucleotides (i.e., microRNAs (miRNAs), small interfering RNAs (siRNAs), PIWI-interacting RNAs (piRNAs)) [ 152 , 153 ]; and long non-coding RNAs (lncRNAs), which have 200 or more nucleotides and which influence cancer cells through mechanisms such as chromatin remodeling, chromatin interaction, competing endogenous RNAs and natural antisense transcripts [ 154 ].…”

Section: Blood Biomarkersmentioning

confidence: 99%

Novel Diagnostic Biomarkers in Colorectal Cancer

Zygulska¹,

Pierzchalski

2022

IJMS

130

View full text Add to dashboard Cite

Colorectal cancer (CRC) is still a leading cause of cancer death worldwide. Less than half of cases are diagnosed when the cancer is locally advanced. CRC is a heterogenous disease associated with a number of genetic or somatic mutations. Diagnostic markers are used for risk stratification and early detection, which might prolong overall survival. Nowadays, the widespread use of semi-invasive endoscopic methods and feacal blood tests characterised by suboptimal accuracy of diagnostic results has led to the detection of cases at later stages. New molecular noninvasive tests based on the detection of CRC alterations seem to be more sensitive and specific then the current methods. Therefore, research aiming at identifying molecular markers, such as DNA, RNA and proteins, would improve survival rates and contribute to the development of personalized medicine. The identification of “ideal” diagnostic biomarkers, having high sensitivity and specificity, being safe, cheap and easy to measure, remains a challenge. The purpose of this review is to discuss recent advances in novel diagnostic biomarkers for tumor tissue, blood and stool samples in CRC patients.

show abstract

MicroRNAs as non-invasive screening biomarkers of colorectal cancer

Cited by 8 publications

References 23 publications

Total RNA extraction from tissues for microRNA and target gene expression analysis: not all kits are created equal

Total RNA extraction from tissues for microRNA and target gene expression analysis: not all kits are created equal

MicroRNA-10a/b are regulators of myeloid differentiation and acute myeloid leukemia

Novel Diagnostic Biomarkers in Colorectal Cancer

Contact Info

Product

Resources

About